ClinicalTrials.gg
CompletedNCT04880031Updated Jul 8, 2026

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

A Phase 2 interventional study of Efimosfermin and Placebo in Nonalcoholic Steatohepatitis (NASH), sponsored by GlaxoSmithKline. Completed at 48 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
61st of 460
231 · median 56
Started
2021
with 56 others
Phase 2
192 of 547
15 open now
Registered
399th of 547
by date
Lead sponsor
8 of 547
GlaxoSmithKline

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 61st largest by enrollment of the 460 interventional ones that give a count, is one of 57 that started in 2021, is one of 192 in phase 2, and was the 399th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)

Keywords

  • BOS-580
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Efimosfermin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Part A and Part B):

  • Participant is either male or female and 18 to 75 years of age inclusive, at the time of signing the
  • Obese participants with (BMI) of ≥ 27 kg/m\^2
  • Hepatic fat fraction (HFF) measured by magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) ≥8%
  • Liver fibrosis assessment based on a vibration controlled transient elastography (VCTE) liver stiffness measurement (LSM) score of 7.0 to 9.9 kPa (Part A only) inclusive or 7.0 to 20.0 kPa (Part B only) inclusive and Liver injury assessment measured by (AST) >25U/L. A qualifying historical (confirmed eligibility based on the central pathology read) supersedes the LSM, controlled attenuation parameter (CAP) score criteria and AST criteria.
  • Histopathologically confirmed F2 or F3 stage NASH on a diagnostic liver biopsy performed during Screening or within 6 months prior to the first day of dosing for historical biopsies (Part B only).
  • History or presence of at least 2 of 4 components of metabolic syndrome: obesity/overweight, dyslipidemia (high triglycerides and/or low high density lipoprotein [HDL]), type 2 diabetes with elevated (HbA1c), and hypertension.

Inclusion Criteria (Part C):

  • Participant must have completed the Part B of the study.
  • Participant willing to undergo liver biopsy at Week 56
  • NASH F stage \<F4 at 24 week assessment in Part B

Inclusion Criteria (Part D):

  • BMI of ≥ 25 kg/m\^2
  • Liver fibrosis based on assessments taken during screening visit
  • Participant should be willing and able to undergo liver biopsy during Screening (if a historical biopsy within 12 months prior to Screening is not available) and per protocol as judged by the Investigator.
  • Other inclusion criteria may apply

Exclusion Criteria (Part A and Part B):

  • Documented clinical, laboratory or radiologic evidence of cirrhosis (compensated or decompensated)
  • Triglycerides ≥ 500 mg/dL
  • Change in body weight (more than 5% self-reported OR 5 kg self-reported change during the previous 3 months from Screening, whichever is smaller)
  • History of type 1 diabetes, diabetic ketoacidosis, or positive glutamic acid decarboxylase (GAD) auto-antibodies (latent diabetes in adults)
  • Hemoglobin A1c > 9.5%
  • Participants with a condition that requires substantial anticoagulant medication may not be eligible for the study enrollment (e.g., deep vein thrombosis).

Exclusion Criteria (Part C):

  • Participants that received their 24 week dose in Part B > 10 weeks prior to enrollment into Part C

Exclusion Criteria (Part D):

  • Other causes of chronic liver disease
  • Documented evidence or history of decompensated liver cirrhosis.
  • History of type 1 diabetes or poorly controlled type 2 diabetes.
  • History of .
  • Use of other drugs.
  • Other exclusion criteria may apply
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
231 participants (actual)

Study arms

  • Experimental
    Cohort A1: Efimosfermin Dose 1 or placebo (PBO)

    Drug: Efimosfermin · Drug: Placebo

  • Experimental
    Cohort A2: Efimosfermin Dose 2 or PBO

    Drug: Efimosfermin · Drug: Placebo

  • Experimental
    Cohort A3: Efimosfermin Dose 3 or PBO

    Drug: Efimosfermin · Drug: Placebo

  • Experimental
    Cohort A4: Efimosfermin Dose 4 or PBO

    Drug: Efimosfermin · Drug: Placebo

  • Experimental
    Cohort A5: Efimosfermin Dose 5 or PBO

    Drug: Efimosfermin · Drug: Placebo

  • Experimental
    Part B: Efimosfermin Dose 1 or PBO

    Drug: Efimosfermin · Drug: Placebo

  • Experimental
    Part C: Efimosfermin Dose 1

    Drug: Efimosfermin

  • Experimental
    Part D: Efimosfermin Dose 6 or PBO

    Drug: Efimosfermin · Drug: Placebo

  • Experimental
    Part D: Efimosfermin Dose 1 or PBO

    Drug: Efimosfermin · Drug: Placebo

Interventions

  • DrugEfimosfermin

    Efimosfermin will be administered by subcutaneous injection

    Also known as: BOS-580

  • DrugPlacebo

    Placebo will be administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Part A, Part B, Part C, and Part D: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)

    The effects of Efimosfermin on safety and tolerability will be assessed.

    Time frame: Until End of study/Early Termination (Day 393)

  2. Part A, Part B, Part C, and Part D: Changes from Baseline in systolic and diastolic blood pressure (BP)

    The effects of Efimosfermin on safety and tolerability will be assessed.

    Time frame: Baseline, Week 12 (Day 85, Part A), Week 24 (Day 169, Part B), Week 56 (Day 393, Part C), and Weeks 36 (Day 253), and 48 (Day 337) (Part D)

  3. Part A, Part B, Part C, and Part D: Changes from Baseline in heart rate

    The effects of Efimosfermin on safety and tolerability will be assessed.

    Time frame: Baseline, Week 12 (Day 85, Part A), Week 24 (Day 169, Part B), Week 56 (Day 393, Part C), and Weeks 36 (Day 253), and 48 (Day 337) (Part D)

  4. Part A, Part B, Part C, and Part D: Number of participants with Grade 3 and Grade 4 laboratory abnormalities

    The effects of Efimosfermin on safety and tolerability will be assessed.

    Time frame: Baseline, Week 12 (Day 85, Part A), Week 24 (Day 169, Part B), Week 56 (Day 393, Part C), and Weeks 36 (Day 253), and 48 (Day 337) (Part D)

Secondary outcomes

  1. Part A only: Efimosfermin serum concentration on Day 8 of the first dose

    The pharmacokinetics (PK) of Efimosfermin will be assessed.

    Time frame: Day 8

  2. Part A only: Efimosfermin serum concentration at the end of the dosing interval (Ctrough)

    The PK of Efimosfermin will be assessed.

    Time frame: Pre-dose at Days 15, 29, 43, 57, 71, 85 and 113 (End of study/Early termination) for bi-weekly schedule; pre-dose on Days 29, 57, 85 and 113 (End of study/Early termination) for the monthly schedule

  3. Part B only: Efimosfermin serum concentration on Day 7

    The PK of Efimosfermin will be assessed.

    Time frame: Day 7

  4. Part B and Part C: Efimosfermin serum concentration at the end of the dosing interval (Ctrough)

    The PK of Efimosfermin will be assessed.

    Time frame: Pre-dose at Days 29, 57, 85, 113, 141, 169, 225, 253, 281, 309, 316, 323, 330, 337, 365 and at Day 393 (End of study/Early Termination)

  5. Part B and Part C: Area under the serum concentration-time curve (AUC) for Efimosfermin for one dosing interval at steady state

    The PK of Efimosfermin will be assessed.

    Time frame: At Days 121, 127, 134, 316, 323, 330 and pre-dose at Days 141 and 337

07

Study locations

48 sites
  • Central Research Associates
    Birmingham, Alabama 35205, United States
  • Arizona Liver Health
    Chandler, Arizona 85224, United States
  • Arizona Liver Health
    Peoria, Arizona 85381, United States
  • Arizona Liver Health
    Tucson, Arizona 85712, United States
  • Liver Institute PPLC
    Tucson, Arizona 85712, United States
  • QLMC
    Tucson, Arizona 85712, United States
  • Alliance Research Institute
    Canoga Park, California 91304, United States
  • Ark Clinical Research
    Fountain Valley, California 92708, United States
  • Fresno Clinical Research Center
    Fresno, California 92720, United States
  • Catalina Research Institute
    Montclair, California 91763, United States
  • Knowledge Research Center
    Orange, California 92868, United States
  • FOMAT Medical Research
    Oxnard, California 93030, United States
  • Inland Empire Clinical Trials
    Rialto, California 92377, United States
  • Southwest General Healthcare Center
    Fort Myers, Florida 33907, United States
  • Covenant Metabolic Specialists - Fort Myers
    Fort Myers, Florida 33912, United States
  • Evolution Clinical Trials
    Hialeah Gardens, Florida 33016, United States
  • Entrust Clinical Research Center
    Kendall, Florida 33176, United States
  • Galenus Group
    Lehigh Acres, Florida 33976, United States
  • G+C Research Group
    Miami, Florida 33126, United States
  • Miami Clinical Research
    Miami, Florida 33155, United States
  • Advanced Clinical Research
    Miami, Florida 33156, United States
  • Admed Research
    Miami, Florida 33173, United States
  • Century Research
    Miami, Florida 33173, United States
  • Panex Clinical Research
    Miami Lakes, Florida 33014, United States
  • Charter Research
    Orlando, Florida 32803, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Covenant Metabolic Specialists - Sarasota
    Sarasota, Florida 34240, United States
  • Tandem Clinical Research
    Marrero, Louisiana 70072, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Coastal Research Institute, LLC
    Fayetteville, North Carolina 28304, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Velocity Clinical Research
    East Greenwich, Rhode Island 02818, United States
  • Accelemed Research
    Austin, Texas 78745, United States
  • Pinnacle Clinical Research - Austin
    Austin, Texas 78757, United States
  • Texas Liver Institute - Austin
    Austin, Texas 78757, United States
  • Apex Mobile Clinical Research
    Bellaire, Texas 77401, United States
  • South Texas Research Institute-Brownsville
    Brownsville, Texas 78520, United States
  • South Texas Research Institute-Edinburg
    Edinburg, Texas 75839, United States
  • Pinnacle Clinical Research - Georgetown
    Georgetown, Texas 78626, United States
  • Houston Research Institute
    Houston, Texas 77079, United States
  • LinQ Research, LLC
    Pearland, Texas 77584, United States
  • Quality Research, Inc
    San Antonio, Texas 78209, United States
  • American Research Corporation at Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research - San Antonio
    San Antonio, Texas 78229, United States
  • Velocity Clinical Research - Waco
    Waco, Texas 76710, United States
  • Olympus Family Medicine
    Salt Lake City, Utah 84117, United States
  • South Ogden Family Medicine
    South Ogden, Utah 84405, United States
  • Liver Institute NorthWest
    Seattle, Washington 98105, United States
08

References and documents

Publications

  • Noureddin M, Kowdley KV, Odrljin T, Bain G, Zhao J, Jeglinski B, Koziel MJ, Loomba R. Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2026 Feb 21;407(10530):794-804. doi: 10.1016/S0140-6736(25)02276-7. Epub 2026 Feb 5. PubMed 41655584 ↗
  • Loomba R, Kowdley KV, Rodriguez J, Kim NJ, Alvarez AM, Morrow L, Jeglinski B, Clawson A, Chowdhury S, Bain G, Odrljin T. Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Gastroenterol Hepatol. 2025 Aug;10(8):734-745. doi: 10.1016/S2468-1253(25)00067-6. Epub 2025 Jun 6. PubMed 40484014 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2025, 48 months.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 48 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2021
First posted
May 10, 2021
StartActual
Sep 30, 2021
Primary completionActual
Oct 27, 2025
CompletionActual
Oct 27, 2025
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04880031
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 10, 2021
Start date
Sep 30, 2021
Primary completion
Oct 27, 2025
Completion
Oct 27, 2025
Last update
Jul 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion